NDA 204683 · Osmotica Pharm Corp
Khedezla
Desvenlafaxine · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 20, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jul 10, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
89
37 Phase 3, 4 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 10, 2013 Original approval · Type 5 - New Formulation or New Manufacturer Summary ReviewLabelReview
2 products under this application
- KHEDEZLA · DESVENLAFAXINE 100MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- KHEDEZLA · DESVENLAFAXINE 50MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Desvenlafaxine" as an intervention, any sponsor and status, largest first.
- Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal WomenPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00683800 · 2,186 participants · Start Jun 2008 · Primary completion May 2010
Drug: desvenlafaxine succinate (DVS) SR; Placebo · For: Vasomotor Symptoms
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 121 sites in all
- Long-Term Safety Of DVS-233 SR In Patients With Major Depressive DisorderPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01309542 · 1,403 participants · Start Aug 2003 · Primary completion Mar 2006
Drug: Desvenlafaxine Succinate · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Mesa, Arizona; Peoria, Arizona · 117 sites in all
- Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01715805 · 1,022 participants · Start Nov 15, 2012 · Primary completion Jun 24, 2016
Drug: Cariprazine; Placebo and 1 more · For: Major Depressive Disorder
Sites: Tucson, Arizona; Little Rock, Arkansas; Cerritos, California · 85 sites in all
- Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01432457 · 924 participants · Start Oct 2011 · Primary completion Jul 2012
Drug: desvenlafaxine succinate sustained-release 50 mg/day; desvenlafaxine succinate sustained-release 100 mg/day and 1 more · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Arcadia, California · 61 sites in all
- Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive DisorderPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00887224 · 874 participants · Start Jun 2009 · Primary completion Mar 2011
Drug: Desvenlafaxine succinate sustained release 50 mg; Desvenlafaxine succinate sustained release 25 mg and 1 more · For: Major Depressive Disorder
Sites: Beverly Hills, California; Encino, California; Los Alamitos, California · 90 sites in all
- Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00797966 · 850 participants · Start May 2009 · Primary completion Jun 2010
Drug: OPC-34712; Placebo and 1 more · For: Major Depressive Disorder
Sites: Arcadia, California; Beverly Hills, California; Escondido, California · 50 sites in all
- Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01469377 · 819 participants · Start Dec 15, 2011 · Primary completion Dec 12, 2013
Drug: Placebo; Cariprazine · For: Major Depressive Disorder
Sites: Garden Grove, California; National City, California; Oceanside, California · 72 sites in all
- Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDDPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00445679 · 807 participants · Start Jul 2007 · Primary completion Feb 2009
Drug: DVS SR; Paroxetine · For: Depressive Disorder, Major
Sites: Beijing, China; Guangdong Province, China; Hunan Province, China · 43 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.
Pillinger T, Arumuham A, McCutcheon RA, et al. · Lancet 2025 · Network Meta-Analysis, Systematic Review
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.
Henssler J, Schmidt Y, Schmidt U, et al. · Lancet Psychiatry 2024 · Systematic Review, Meta-Analysis
- New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE, McKenzie JE, Bailey AP, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
Zhou X, Teng T, Zhang Y, et al. · Lancet Psychiatry 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A, Ajmera M, Gao E, et al. · Menopause 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Osmotica Pharm Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.